Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 6/20 | 0.40 |
| ▸ | IDH2 | P48735 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.37 |
| ▸ | HTR3B | O95264 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16419621 | 0.84 | L3MBTL1 (0.44) | L3MBTL1CYP3A4TSHRIDH1IDH2 | |
| SCHEMBL19465878 | 0.82 | L3MBTL1 (0.36) | L3MBTL1CYP3A4TSHRIDH1IDH2 | |
| SCHEMBL29931101 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CYP3A4TSHRIDH1IDH2 | |
| SCHEMBL12891555 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CYP3A4TSHRIDH1IDH2 | |
| SCHEMBL30108505 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CYP3A4TSHRIDH1IDH2 | |
| SCHEMBL24774178 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CYP3A4TSHRIDH1IDH2 | |
| SCHEMBL29793734 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CYP3A4TSHRIDH1IDH2 | |
| SCHEMBL1645018 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CYP3A4TSHRIDH1IDH2 | |
| SCHEMBL21438046 | 0.82 | L3MBTL1 (0.43) | L3MBTL1CYP3A4TSHRIDH1IDH2 | |
| SCHEMBL786336 | 0.82 | PGK1 (0.39) | CYP3A4TSHRALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870577-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2025-03-19 | — | — | EP | disclosed |
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-114901660-B | Substituted bicyclic compounds useful as T cell activators | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | THE CLEVELAND CLINIC FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2023230038-A1 | PIPERIDINYL-METHYLPURINE PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230026-A1 | PIPERIDINYL-METHYLPURINE BENZENES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-20090233897-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME CORP. | 2009-09-17 | — | — | US | disclosed |
| WO-2009088986-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090137594-A1 | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments | GRUENENTHAL GMGH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | L3MBTL1 4132/4885CYP3A4 1611/4885TSHR 4613/4885 |
| US-20080076773-A1 | Aminopiperidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | L3MBTL1 4413/4885CYP3A4 160/4885TSHR 3792/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | L3MBTL1 3938/4885CYP3A4 1459/4885TSHR 4595/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | L3MBTL1 4680/4885CYP3A4 212/4885TSHR 3629/4885 |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | L3MBTL1 3761/4885CYP3A4 761/4885TSHR 877/4885 |
| US-20090137594-A1 | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments | FIBP, PFAS, FPR3 | L3MBTL1 4250/4885CYP3A4 1233/4885TSHR 3312/4885 |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | L3MBTL1 3038/4885CYP3A4 4521/4885TSHR 2035/4885 |
| US-20240239772-A1 | PROTEASE INHIBITORS AND METHODS OF USE | ACE2, ACE, TMPRSS2 | L3MBTL1 2370/4885CYP3A4 459/4885TSHR 4756/4885 |
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | L3MBTL1 3263/4885CYP3A4 745/4885TSHR 3119/4885 |
| US-20090233897-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | L3MBTL1 519/4885CYP3A4 1526/4885TSHR 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.